Dyne Therapeutics
246 hedge funds and large institutions have $4.23B invested in Dyne Therapeutics in 2026 Q2 according to their latest regulatory filings, with 49 funds opening new positions, 88 increasing their positions, 76 reducing their positions, and 28 closing their positions.
75% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 28
24% more capital invested
Capital invested by funds: $3.4B → $4.23B (+$827M)
16% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 76
8% more funds holding
Funds holding: 228 → 246 (+18)
1.46% more ownership
Funds ownership: 113.84% → 115.3% (+1.5%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
76% less call options, than puts
Call options by funds: $1.05M | Put options by funds: $4.43M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$42.7M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$29.9M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$26.1M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$21.4M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$18.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AVLSA
Atlas Venture Life Science Advisors
Cambridge,
Massachusetts
|
-$43.3M |
| 2 |
PA
Perceptive Advisors
New York
|
-$36.8M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$15.8M |
| 4 |
FIS
FCPM III Services
Naarden,
Netherlands
|
-$14.8M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
-$14.1M |
DYN Hedge Fund Activity: Q2 2026 in Review
246 of the 8,300 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q2 2026, worth a combined $4.23B — up 24% from $3.4B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new DYN positions and 28 closed out — a net gain of 21 holders — while 88 added to existing stakes and 76 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $42.7M. The largest seller was Atlas Venture Life Science Advisors, cutting an estimated $43.3M.
- 246 institutional investors held Dyne Therapeutics (DYN) as of Q2 2026, up from 228 in Q1 2026.
- Funds reported $4.23B of Dyne Therapeutics stock for Q2 2026, up 24% quarter-over-quarter.
- 49 funds opened new Dyne Therapeutics positions in Q2 2026 and 28 closed out, a net change of +21 holders.
- The largest Dyne Therapeutics buyer in Q2 2026 was Fidelity Investments, an estimated $42.7M added.
- The largest Dyne Therapeutics seller in Q2 2026 was Atlas Venture Life Science Advisors, an estimated $43.3M sold.
Based on aggregated 13F filings for Q2 2026.